Logo-ipp
Submitted: 06 Feb 2022
Accepted: 18 May 2022
ePublished: 05 Jun 2022
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Immunopathol Persa. Inpress.
doi: 10.34172/ipp.2022.31368
  Abstract View: 697

Original

Evaluating serum levels of interleukin-8 and interleukin-17 in patients with COVID-19 and their correlation with disease severity

fatemeh saebi 1 ORCID logo, seyed mohammad ali malaekeh 2 ORCID logo, seyed mohammad bagher mohammadi 2 ORCID logo, narges chamkouri 2 ORCID logo, ali saeedi Boroujeni 2,3 ORCID logo, zahra koolivand 2* ORCID logo

1 School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2 Abadan University of Medical Sciences, Abadan, Iran
3 Department of Immunology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
*Corresponding Author: *Correspondence to Zahra Koolivand, Email: z.koolivand@abadanums.ac.ir, , Email: k.saye80@yahoo.com

Abstract

Introduction: In COVID-19 patients, those with underlying disease are relatively more susceptible to respiratory viral infections and are more likely to develop severe symptoms compared to people without underlying disease.

Objectives: This study aimed to evaluate the serum levels of interleukin (IL)-8 and IL-17 in patients infected with severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) and patients with underlying disease.

Patients and Methods: Serum samples were collected before administration of any antiviral and/or immunosuppressive drug. Around 64 adult patients with COVID-19 and 12 adult patients with underlying disease were compared with 16 healthy subjects as controls. The cytokine levels were assessed by ELISA (enzyme-linked immunosorbent assay) method and the statistical analysis was carried out using the one-way analysis of variance (ANOVA).

Results: The average levels of these cytokines in the severe group were significantly higher than those in the mild and control group (r=0.48, P<0.016); it is worth noting that patients with underlying disease also displayed a higher level of these cytokines than those with mild and control groups ( r = 0.283, P<0.049). No significant differences were observed between severe and other patients with underlying disease and also between mild and control groups.

Conclusion: Our data indicate that IL-17 and IL-8 are involved in inducing and mediating proinflammatory responses and that the elevated level of these inflammatory cytokines could be the effective ground in the severity of COVID-19 and being susceptible in people with underlying disease. Thus, providing a platform of inflammatory signature cytokines in COVID-19 patients with underlying co-morbidities or without as well as in non-COVID-19 patients with underlying diseases might provide a promising solution to COVID-19 disease.


Citation: Saebi F, Malaekeh SMA, Mohammadi SMB, Chamkouri N, Saeedi Boroujeni A, Koolivand Z. Evaluating serum levels of interleukin-8 and interleukin-17 in patients with COVID-19 and their correlation with disease severity. Immunopathol Persa. 2022;x(x):e31368. DOI:10.34172/ ipp.2022.31368.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 698

Your browser does not support the canvas element.


PDF Download: 0

Your browser does not support the canvas element.